medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2005, Number 4

<< Back Next >>

Rev Mex Urol 2005; 65 (4)

Ureteral stents: What will the future provide?

Vásquez-Lastra C, Castro GA, Figueroa GR, Cisneros MB, Contreras EA, Lomelín JP, Mérigo AJ

Language: Spanish
References: 51
Page: 269-276
PDF size: 68.99 Kb.


ABSTRACT

Ureteral stents have become an invaluable tool in our armamentarium due to the technological advances in the recent years. Thanks to this technology, we have been able to transform aggressive surgeries for alleviating obstructive pathology into an ambulatory, minimally invasive procedure. Modern ureteral stents have a low friction coefficient, are thermosensitive and have and hydrophilic layer that allow an easy placement in the urinary tract. Despite these advances, we are far from having an ideal stent. In this paper we will show the advances in ureteral stents, regarding new materials, coatings and designs, which are intended to modify modern urology as we know it.


REFERENCES

  1. Gibbons RR, Correa RJ, Cummings KB, Mason JT. Experience with indwelling ureteral stent catheters. J Urol 1976; 115: 22.

  2. Finney RP. Experience with new double J ureteral catheter stent. J Urol 1978; 120: 678.

  3. Cormio L, Talja M, Koivusalo A, Mäkisalo H, Wolf H, Rutu M. Biocompatibility of various indwelling double-J stents. J Urol 1995; 153: 494.

  4. Mardis HK, Kroeger RM. Ureteral stents materials. Urol Clin North Am 1988; 15: 471.

  5. Marx M, Bettmann MA, Bridge S, Brodsky G, Boxt LM, Richie JP. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J Urol 1988; 139: 180.

  6. Prior JL, Langley MJ, Jenkins AD. Comparison of symptom characteristics of indwelling ureteral catheters. J Urol 1991; 145: 719.

  7. Pollard SG, Macfarlane R. Symptoms arising from double-J ureteral stents. J Urol 1988; 139: 37.

  8. Bregg K, Riehl RA Jr. Morbidity associated with indwelling internal ureteral stents after shock wave lithotripsy. J Urol 1989; 141: 510.

  9. Irani J, Siquier J, Pires C, Lefebvre O, Dore B, Aubert J. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int 1999; 84: 276.

  10. 10.Pugach JL, Valerio D, Mittelman MW, Bruce AW, DiCosmo F. Antibiotic hydrogel coated foley catheters for prevention of urinary tract infection in a rabbit model. J Urol 1999; 162: 883.

  11. 11.Monga M, Klein E, Castañeda-Zúñiga WR, Tomas R. The forgotten indwelling ureteral stent: a urological dilemma. J Urol 1995; 153: 1817.

  12. 12.Darren TB, Knudsen BE, Watterson JD, Cadieux PA, Reid G, Denstedt JD. Urinary Tract Biomaterials. J Urol 2004; 171: 2438.

  13. 13.Marx M, Bettmann MA, Bridge S, Brodsky G, Boxt LM, Richie JP. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J Urol 1988; 139: 180.

  14. 14.Densted JD, Wollin TA, Reid G. Biomaterials used in urology: current signs of biocompatibility, infection, and encrustation. J Endourol 1998; 12: 493.

  15. 15.Yu DS, Yang TH, Ma CP. Snail-headed catheter retriever: A simple way to remove catheters from female patients. J Urol 1995; 154: 167.

  16. 16.Taylor WN, Mcdougall IT. Minimally invasive ureteral stent retrieval. J Urol 2002; 168: 2020-3.

  17. 17.Kulkarni RK, Pani KC, Neuman C, et al. Polylactic acid for surgical implants. Arch Surg 1966; 93: 839.

  18. 18.Drinker HR. Polyglycolic acid sutures in genitourinary surgery. Urology 1974; 3: 215.

  19. Olweny EO, Landman J, Andreoni C, Collyer W, Kerbel K, Onciu M, et al. Evaluation of the use of a biodegradable ureteral stents after retrograde endopylotomy in a porcine model. J Urol 2002; 167: 2198.

  20. 20.Auge BK, Ferraro RF, Madenjian AR, Premigner GM. Evaluation of a dissolvable ureteral drainage stent in a Swine model. J Urol 2002; 168: 8008.

  21. 21.Lingerman JE, Preminger GM, Berger Y, Denstedt JD, Goldstone L, Segura JW, et al. Use of a temporary ureteral drainage stent after uncomplicated ureteroscopy: results from a Phase II clinical trial. J Urol 2003; 169: 1682.

  22. 22.Schlick RW, Planz K. In vitro results with special plastics for biodegradable endoureteral stents. J Endourol 1998; 12(5): 451.

  23. 23.Amiel GE, Yoo JJ, Kim BS, Atala A. Tissue engineered stents created from chondrocytes. J Urol 2001; 165: 2091.

  24. 24.Sigwart U, Puel J, Mirkovitch B, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. New Engl J Med 1987; 316: 701.

  25. 25.Adam A, Chetty N, Roddie M, Yeung E, Benjamín IS. Self-expandable stainless steel endoprosthesis for treatment of malignant bile duct obstruction. Amer J Radiol 1991; 156: 321.

  26. 26.Kulkarni R, Bellamy E. Nickel-titanium shape memory alloy memokath 051 ureteral stent for managing long-term ureteral obstruction 4-year experience. J Urol 2001; 166: 1750.

  27. 27.Barbalias GA, Liatsikos EN, Kalogeropoulou C, Kernabatidis D, Zabakis PL, Athanasopoulos A. Externally coated ureteral metallic stents: an unfavorable clinical experience. Eur Urol 2002; 42: 276.

  28. 28.Barbalias GA, Siablis D, Liatsikos EN, Karnabatidis D, Yarmenitis S, Bouropoulos K. Metal stents: a new treatment of malignant ureteral obstruction. J Urol 1997; 158: 54.

  29. 29.Hekimoglu B, Men S, Pinar A, Ozmen E, Soylu SO, Conkbayir I. Urothelial hyperplasia complicating use of metal stents in malignant ureteral obstruction. Eur Radiol 1996; 6: 675.

  30. 30.Braf Z, Chen J, Soler M, Matzkin H. Intraprostatic metal stents (Prostakath and Urospiral): more than 6 years clinical experience with 110 patients. J Endourology 1996; 10: 555.

  31. 31.Tunney MM, Gorman SP. Evaluation of a poly(vinyl pyrollidone)-coated biomaterial for urological use. Biomaterials 2002; 23(23): 4601-8.

  32. 32.Gorman SP, Tunney MM, Keane PF, et al. Characterization and assessment of a novel poly(ethylene oxide)/polyurethane composite hydrogel (Aquavente) as a ureteral stent biomaterial. J Biomed Mater Res 1998; 39(4): 642-9.

  33. 33.Pugach JL, DiTzio V, Mittelman MW, Bruce AW, et al. Antibiotic hydrogel coated foley catheters for prevention of urinary tract infection in a rabbit model. J Urol 1999; 162: 883-7.

  34. 34.Riedel CR, Witkowsky M, Plas E, et al. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int J Antimicrob Agents 2002; 19(6): 507-10.

  35. 35.Zupkas P, Parsons CL, Percival C, Monga M. Pentosampolysulfate coating of silicone reduces encrustation. J Endourol 2000; 14: 483.

  36. 36.Stickler DJ. Biomaterials to prevent nosocomial infections: is silver the gold Standard? Curr Opin Infect Dis 2000; 13(4): 389-93.

  37. 37.Multanen M, Tammela TL, Laurila M, et al. Biocompatibility, encrustation and biodegradation of ofloxacine and silver nitrate coated poly-L-lactic acid stents in rabbit urethra. Urol Res 2002; 30(4): 227-32.

  38. 38.Stickler DJ, Evans A, Moris N, et al. Strategies for the control of catheter encrustation. Int J Antimicrob Agents 2002; 19(6): 499-506.

  39. 39.Sidhu H, Ogden SE, Lung HY, Luttge BG, Baetz AL, Peck AB. DNA sequencing and expression of the formyl coenzyme A transferasa gene, frc, from oxalobacter formigenes. J Bacteriol 1997; 179: 3378.

  40. 40.Watterson JD, Cadieux PA, Beiko DT, Cook AJ, Burton JP, Harbottle RR, et al. Oxalate-degrading enzimes from oxalobacter formigenes: A novel device coating to reduce urinary tract biomaterial-related encrustation. J Endourol 2004; 17: 269.

  41. 41.Granada JF, Kaluza GL, Raizner A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep 2003; 5(4): 308-16.

  42. 42.Mittelman M, Bucay-Cuto W, Li J, et al. In vitro antimicrobial release profile of a new triclosan-eluting ureteral stent. J Urol 2004; 171 (4 Suppl.): 443.

  43. 43.Kallinteri P, Antimisiaris SG, Karnabatidis D, et al. Dexametasone incorporating liposomes: An in vitro study of their applicability as s slow releasing delivery system of dexamethasone from coverd metallic stents. Biomaterials 2002; 23(24): 4819-26.

  44. 44.Perlstein I, Connolly JM, Cui X, et al. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther 2003; 10(17): 1420-8.

  45. 45.Reid G, Habash M, Vachon D, et al. Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention on biofilm formation. Int J Antimicrob Agents 2001; 17(4): 317-9.

  46. 46.Riedl CR, Plas E, Hubner WA, et al. Bacterial colonization of ureteral stents. Eur Urol 1999; 36(1): 53-9.

  47. 47.Nickel JC, Costerton JW, Malean JC, Olson M. Bacterial biofilms. Influence on the patogenesis, diagnosis and treatment of urinary tract infections. J Antimicrob Chemother 1994; 33: 31.

  48. 48.Stoller ML, Schwartz BF, Frigstad JR, et al. An in vitro assessment of the flow characteristics of spiral-ridged and smooth-walled JJ ureteric stents. BJU Int 2000; 85(6): 628-31.

  49. 49.Liatsikos EN, Hom D, Dinlenc CZ, et al. Tail stent versus re-entry tube: A randomized comparison after percutaneous stone extraction. Urology 2002; 59(1): 15-19.

  50. 50.Chahin F, Dwivedi AJ, Paramesh A, et al. The implications of lighted ureteral stenting in laparoscopic colectomy. JSLS 2002; 6(1): 49-52.

  51. 51.Taylor WN, McDougall IT. Minimally invasive ureteral stent retrieval. J Urol 2002; 168(5): 2020-3.




2020     |     www.medigraphic.com